Drug intelligence / Profile preview

NLS-11

Development stage: Preclinical
Lead developer: NLS Pharmaceutics
Modality: Allosteric Modulators → Classical Binding Small Molecules → Small Molecules

Overview

NLS-11 (benedin) is a novel small molecule drug in preclinical development by NLS Pharmaceutics for the treatment of Kleine-Levin Syndrome (KLS), an ultra-rare sleep disorder characterized by recurrent episodes of hypersomnia and behavioral changes. The compound is described as a circadian rhythm modulator, with preclinical studies demonstrating benefit on hypersomnia symptoms and exhaustion associated with KLS in animal models. There are currently no approved treatments for KLS worldwide. Patent filings suggest potential applications in other rare sleep disorders and neurodegenerative diseases, such as Lewy body dementia[4][5][6].

Other names: benedin

Targets

DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on NLS-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NLS-11.

Explore the full profile